AChE/MAO dual inhibitors are believed to be more effective in treating AD, and ladostigil showed a neuroprotective ability and stimulated the processing of amyloid precursor protein (APP) alpha through AChE/MAO dual inhibition [10, 11]. The gene discussed is ACHE; the disease is Alzheimer disease.